Stroke
Upcoming SlideShare
Loading in...5
×
 

Like this? Share it with your network

Share

Stroke

on

  • 2,199 views

 

Statistics

Views

Total Views
2,199
Views on SlideShare
2,199
Embed Views
0

Actions

Likes
4
Downloads
205
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Stroke Presentation Transcript

  • 1.  Stroke in Malaysia Definition of stroke Classification of stroke Diagnosis of stroke Cause & pathophysiology Risk factors Stroke investigations Stroke Management
  • 2. Stroke is the third largest cause of death inMalaysia. Only heart diseases and cancer killmore. It is considered to be the single mostcommon cause of severe disability, and everyyear, an estimated 40,000 people in Malaysiasuffer from stroke. Anyone can have astroke, including children, but the vast majority ofthe cases affect adults.
  • 3. A stroke is a clinical syndrome characterized by rapidly developing clinical symptoms and/or signs of focal, and at times global, loss of cerebral function, with symptoms lasting more Functions of the brain than 24 hours orleading to death, with no apparent cause other that ofvascular origin
  • 4.  Total Anterior Circulation Stroke ( TAC) All of• Hemiplegia contralateral to the cerebral lesion , usually with ipsilateral hemisensory loss• Hemianopia contralateral to cerebral lesion• New diturbance of higher cerebral function ( dysphasia , visuospatial ) Lacunar Stroke ( LAC )• Pathological definition• Occlusion of a single deep ( LS ) perforating artery• 5% can be due to haemorrhage• Occurs at strategic sites• More likely seen on MRI than CT scan• Classical lacunar syndromes correlated with relevant lacunes at autopsy
  • 5.  Partial Anterior Circulation Stroke ( PAC ) Any of• Motor / sensory deficit + hemianopia• Motor / sensory deficit + new higher cerebral dysfunction• New higher cerebral dysfunction + hemianopia• New higher cerebral dysfunction alone• A pure motor / sensory deficit less extensive than for LAC ( eg. confined to one limb, or to face and hand but not to whole arm) Posterior Circulation Stroke ( POC ) Any of• Ipsilateral cranial nerve palsy ( single / multiple ) with contralateral motor and/or sensory deficit• Bilateral motor and/or sensory deficit• Disorder of conjugate eye movement (horizontal/vertical)• Cerebellar dysfunction without ipsilateral long tract sign• Isolated hemianopia or cortical blindness• Other signs include Horner‟s sign , nystagmus, dysarthria, hearing loss, etc.
  • 6. Anterior ( carotid ) artery circulation Posterior ( vertebrobasilar ) artery circulation Middle cerebral artery • Homonymous hemianopia• Aphasia ( dominant hemisphere) • Cortical blindness• Hemiparesis/plegia • Ataxia• Hemisensory loss/disturbance • Dizziness or vertigo• Homonymous hemianopia • Disarthria• Parietal lobe • Diplopia dysfunction, e.g.astereognosis, agraph • Dysphagia aesthesia, impraired two-point • Homer‟s syndrome discrimination, sensory and visual • Hemiparesis or hemisensory loss inattention, left-right dissociation and contralateral to the cranial nerves acalculia palsy Anterior cerebral artery • Cerebellar signs• Weakness of lower limb more than upper limb
  • 7.  Metabolic/toxic encephalopathy ( hypoglycaemia, non-ketotic hyperglycaemia, Wernicke-Korsakoff syndrome, drug intoxication) Epileptic seizures ( postictal Todd‟s paresis) Hemiplegic migraine Structural intracranial lesions ( e.g.subdural haematoma, brain tumor, arteriovenous malformation) Encephalitis ( e.g.heerpes simplex virus), brain abscess, tuberculoma Head injury Hypertensive encephalopathy Relapsing Multiple Sclerosis Conversion disorders Hyperviscosity syndrome Peripheral nerve lesions ( e.g. Guillain- Barre Syndrome)
  • 8.  Ischaemic stroke :• Atherothromboembolism (50%)• Intracranial small vessel disease(penetrating artery disease) (25%)• Cardiogenic embolism(20%)• Other causes include: arterial dissection trauma vasculitis (primary/secondary) A blood clots get stuck in an metabolic disorders artery and blocks the blood congenital disorders flow.And other less common causes such asmigraine, pregnancy, oral contraceptives, etc.
  • 9. Ischaemic strokeAtherothrombotic Penetrating Other Embolism cerebrovascular artery disease causes disease (“lacunes”) Cardiogenic Atrial Large artery fibrillation atheroma Hypoperfusion Valve disease Venticular thrombi PFO and ASA Intracardiac tumour ExtracranialIntracranial Prothrombotic Artery to artery Carotid stenosis states:Dissection,Arteritis, AorticArchAtheroma Migraine, Drug abuse
  • 10.  Haemorrhagic stroke :• An intracerebral haemorrhage.• A subarachnoid haemorrhage. When an artery bursts blood is forced into the brain tissue, damaging cells so that area of the brain cant function.
  • 11.  Age. Strokes are more common in people over 55, and the incidence continues to rise with age. Gender. Men are at a higher risk of stroke than women, especially under the age of 65. Family history. Having a close relative with a stroke increases the risk, possibly because factors such as high blood pressure and diabetes tend to run in families.
  • 12.  High Blood Pressure ( systolic and diastolic) Cigarette smoking Diabetes mellitus Atrial Fibrillation Coronary heart disease Hyperlipidaemia Obesity & physical inactivity Raised Homocysteine levels High dietary salt intake Heavy alcohol consumption Previous stroke
  • 13. The following investigations for patients withischaemic stroke are recommended in order toachieve the following objectives:1. Confirm the diagnosis2. Determine the stroke mechanism3. Risk stratification and prognostication4. Identify potentially treatable large obstructive lesions of the cerebrovascular circulation
  • 14. ON ADMISSION Full blood count ( Exclude anaemia, polycythaemia, thrombocytosis, thrombocytopenia, etc.) Random blood glucose (Exclude hypoglycemia, new diagnosis of diabetes mellitus) Urea & electrolytes (Hydration status, excludes electrolyte imbalances) Clotting profile (if thrombosis is considered) (Baseline)NEXT DAY Lipid profile(fasting) Glucose (fasting) OPTIONAL TESTS ( in selected patients) VDRL Autoimmune screen (ESR, antinuclear Factor, Rheumatoid Factor, anti double stranded DNA antibodies, C3 C4 levels, etc.) Thrombophilia screen & lupus anticoagulant (Serum fibrinogen, Anti- thrombin III, Protein C, Protein S, Factor V-Leyden, anti-phospholipid antibodies) Homocysteine (fasting) C reactive protein
  • 15.  12 lead ECG ( Mandatory) Ambulatory ECG ( for suspected arrhythmias or sinoatrial node disease)
  • 16. FOR ALL SUSPECTED STROKE Chest x-ray ( Mandatory) CT brain ( The emergency neuroimaging scan of choice for all patients. Differentiates haemorrhage from infarction. Confirm site of lesion, cause of lesion, extent of brain affected)IN SELECTED PATIENTS ECHO cardiography ( For suspect cardioembolism, assess cardiac function) MRI(magnetic resonance imaging) (Sensetive. Not available in emergency setting, limited by expense. Useful tool to selecct patients for thrombolysis where available) Carotid duplex Ultrasound (Allows identification of extracranial vessel disease) Transcranial Doppler Ultrasound (Identifies intracranial vessel disease with prognostic and therapeutic implications)
  • 17.  MR angiography(MRA) (Non invasive tool to assess intra- and extra- cerebral circulation. Objective assessment of vessel stenosis) CT angiography( multislice CT scan)( Non invasive tool to assess intra- and extra-cerebral circulation. Involves intravenous contrast injection) MR venography ( In suspected cerebral venous thrombosis) Contrast angiogram ( Gold standard assessment of cerebral vasculature. Reserved for patients planned for intervention) MR angiography showing blockageAreas of the brain affected with of the artery in the brain (arrow)stroke ( circled red circles)
  • 18. Symptoms & signs suggestive of Stroke Symptoms & signs persist > 1 hour Acute Care Urgent Clinical Evaluation Urgent brain CT Blood tests ECG Ischaemic Stroke Brain CT normal or shows Haemorrhagic Stroke acute infarction ( ICH / SAH ) Brain CT shows haemorhage Specific Stroke therapyThrombolytic therapy ( if no contraindications Neurosurgical Evaluation , Antiplatelet therapy & Treatment
  • 19. Acute Stroke Care Stroke Unit ( if available ) Airway , Breathing , Circulation Hydration. Blood Pressure monitoring Neurological Status monitoring Anticipate & treat complications Begin rehabilitation NeurorehabilitationMultidisciplinary Team Approach Further Investigations Education Proper Positioning Establish Stroke Patient & Early mobilization subtype and underlying Caregiver Physiotherapy cause Occupational therapy Cardio & Speech therapy Cerebrovascular Risk Treat spasticity Assessment Treat depression Secondary Prevention Antiplatelet therapy Treat risk factors Treat specific underlying cause
  • 20. Factors recommendationHypertension Treat medically if BP>140mmHg systolic and/or>90mmHg diastolic. Lifestyle changes if BP between 130-139mmHg systolic and/or 80-89mmHg diastolic. Target BP for diabetics is <130mmHg systolic and <80mmHg diastolic. Hypertension should be treated in the very elderly(age >70yrs) to reduce risk of stroke.Diabetes mellitus Strict blood pressure control is important in diabetics. Maintain tight glycaemic control.Hyperlipidaemia High risk group keep LDL<2.6mmol/l. 1 or more risk factors: keep LDL<3.4mmol/l. No risk faktor: keep LDL<4.2mmol/l.Smoking Cessation of smoking.
  • 21. Aspirin therapy 100mg aspirin every other day may be useful in women above the age of 65Post menopausal Oestrogen based HRT is not recommended for primaryHormone stroke preventionReplacementtherapyAlcohol Avoid heavy alcohol consumption.
  • 22. Factors RecommendationAirway &Breathing Ensure clear airway and adequate oxygenation. Elective intubation may help some patients with severely increased ICP.Mobilization Mobilize early to prevent complicationsBlood Pressure Do not treat hypertension if<220mmHg systolic or<120mmHg diastolic. Mild hypertension is desirable at 160-180/90-100mmHg. Blood pressure reduction should not be drastic. Proposed substances: Labetolol 10-20 mg boluses at 10 minute intervals up to 150-300 mg or 1 mg/ml infusion, 1-3 mg/min or Captopril 6.25-12.25 mg orally.Blood Glucose Treat hyperglycaemia (Random blood glucose>11mmol/l) with insulin. Treat hypoglycaemia (Random blood glucose<3mmol/l) with glucose infusion.
  • 23. Nutrition Perform a water swallow test. Insert a nasogastric tube if the patient fails the swallow test. PEG is superior to nasogastric feeding only if prolonged enteral feeding is required.Infection Search for infection if fever appears and treat with appropriate antibiotics early.Fever Use anti-pyretics to control elevated temperatures.Raised Hyperventilate to lower intracranial pressure.Intracranial Mannitoll (0.25 to 0.5 g/kg) intravenously administeredPressure over 20 minutes lowers intracranial pressure and can be given every 6 hours. If hydrocephalus is present, drainage of cerebrospinal fluid via an intraventicular catheter can rapidly lower intracranial pressure. Hemicraniectomy and temporal lobe resection have been used to control intracranial pressure and prevent herniation among those patients with very large infarctions of cerebral hemisphere. Ventriculostomy and suboccipital craniectomy is effective in relieving hydrocephalus and brain stem compression caused large cerebellar infarctions.
  • 24. Treatment Recommendationsrt-Pa In selected patients presenting within 3 hours: IV rt-Pa (0.9mg/kg, maximum 90mg ) with 10% given as a bolus followed by an infusion over one hour.Aspirin Start aspirin within 48 hours of stroke onset. Use of aspirin within 24 hours of rt-Pa is not recommendedAnticoagulants The use of heparins (unfractionated heparin, low molecular weight heparin or heparinoids) is not routinely recommended as it does not reduce the mortality in patients with acute ischaemic stroke.Neuroprotective A large number of clinical trials testing a variety ofAgents neuroprotective agents have been completed. These trials have thus far produced negative results. To date, no agent with neuroprotective effects can be recommended for the treatment of patient with acute ischaemic stroke at this time.
  • 25. Treatment RecommendationsAspirin All patients should be commenced on aspirin within 48 hours of ischaemic strokeWarfarin Adjusted-dose warfarin may be commenced within 2-4 days after the patient is both neurologically and medically stable.Heparin Adjusted-dose unfractionated heparin may be sterted(unfractionated) concurrently for patients at very high risk of embolism.Anticoagulation Anticoagulation may be delayed for 1-2 weeks if there has been substantial haemorrhage. Urgent routine anticoagulation with the goal of improving neurological outcomes or preventing early recurrent stroke is not recommended. Urgent anticoagulation is not recommended for treatment of patients with moderate-to-large cerebral infarcts because of a high risk of intracranial bleeding complications
  • 26. Major risk Additional risk Recommendationconditions factorsAtrial High risk:Fibrillation Age>75years; Long-term warfarin for patients with 1 or Previous stroke/TIA; more high-risk factors Mitral valve disease; Congestive heart failure; hypertension Moderate risk: Age 65-75 years; Long-term warfarin for patients with 2 or Coronary artery more moderate risk factors disease, peripheral Warfarin or aspirin for patients with 1 artery disease; moderate risk factor Diabetes; Aspirin 75-325mg daily is sufficient for Active thyroid patients<65years of age with „lone‟ AF disease. and no additional risk factors present
  • 27. Prosthetic Moderate risk:Heart Valves Bileaflet or tilting(Mechanical) disk aortic valves in Life-long warfarin NSR High risk: Bileaflet or tilting Life-long warfarin (target INR 3.0; disk aortic valves in range 2.5-3.5) AF or NSR Very high risk: Caged-ball and caged-disk designs; Life-long warfarin (target INR 3.0; documented range 2.5-3.5) stroke/TIA despite plus aspirin 75-150mg daily adequate therapy with warfarinBioprosthetic High risk:heart valves AF; left atrial If high risk factors present, consider thrombus at surgery; warfarin for 3-12 months or longer previous CVA/TIA For all other patients, give warfarin or systemic embolism for 3 months post-op, then aspirin 75- 150mg daily
  • 28. Mitral High risk:Stenosis AF; previous If high risk factors present, consider stroke/TIA; left atrial long-term warfarin thrombus; left atrial For all other patients start aspirin 75- diameter>55mm on 150mg daily echo.MI and LV High risk:dysfunction Acute/recent MI(<6 If risk factors present without LV mos); extensive thrombus: consider warfarin for 3-6 infarct with anterior months followed by aspirin 75-150mg wall involvement; daily previous stroke/TIA Very high risk: Severe LV dysfunction If LV thrombus is present, consider (EF<28%); LV warfarin for 6-12 month aneurysm ; spontaneous echo contrast; LV For dilated cardiomyopathies thrombus; dilated including peripartum, consider long- non-ischaemic term warfarin cardiomyopathies.Recomended warfarin dose INR target 2.5(range2.0-3.0)unless stated otherwise
  • 29. Factors RecommendationsTreatmentAntiplatelets Single agentAspirin The recommended dose of aspirin is 75mg to 325mg daily. Alternatives:Clopidogrel The recommended dose is 75mg daily.Ticlopidine The recommended dose is 250mg twice a day. Double therapyAspirin+clopidogrel In selected high risk patients only when benefit outweighs riskAnti-hypertensive ACE-inhibitor based therapy should be used totreatment reduce recurrent stroke in normotensive and hypertensive patients. ARB-based therapy may benefit selected high risk populations.
  • 30. Lipid lowering Lipid reduction should be considered in all subjects with previous ischaemic strokes.Diabetic control All diabetic patients with previous stroke should improve glycaemic control.Cigarette smoking All smokers should stop smoking.
  • 31. Treatment RecommendationsCarotid Indicated for most patients with stenosis of 70-99% after aEndarterectomy recent ischaemic event in centres with complication rates(CEA) less than 6% Earlier invention (within 2 weeks) is more beneficial. May be indicated for patients with stenosis of 50-69% after a recent ischaemic event in centres with complication rates of less than 6% CEA is not recommended for patients with stenosis of less than 50% Patients should remain on antithrombotic therapy before and after surgery.Carotid CAS represents a feasible alternative to carotidangioplasty & endarterectomy for secondary stroke prevention whenstenting (CAS) surgery is undesirable, technically difficult or inaccessible. Distal protection devices should be used during the procedure and anti-platelet agents such as clopidogrel be intiated. The long-term safety and efficacy of CAS is not knownIntracranial Role of AS in intra-cranial stenoses, asymptomaticAngioplasty & Stenoses and acute stroke is unclear and not recommendedstenting ( IAS)
  • 32. Treatment RecommendationsAspirin Young Ischaemic stroke If the cause is not identified, aspirin is usually given. There are currently no guidelines on the appropriate duration of treatment. Cerebral Venous thrombosisHeparin Anticoagulation appears to be safe, and cerebral haemoffhage is not a contra-indication for anticoagulation.Warfarin Simultaneous oral warfarin should be commenced. The appropriate length of treatment is unknown.Endovascular It is currently considered for patients with extensivethrombolysis disease and clinical deterioration
  • 33.  Anti-platelets• Ciclo-oxygenase inhibitors Acetylsalicylic acid ( Aspirin)• Adenosine Diphosphate Receptor Antagonists Ticlopidine Clopidogrel• Other Antiplatelet Agents Dipyridamole• GP IIb/ IIIa Abciximab Eptifibatide Tirofiban
  • 34.  Anticoagulants• Unfractionated Heparin ( UFH ) Heparin• Low Molecular Weight Heparin ( LMWH) Nadroparin Enoxaparin Fondaparinux Wafarin Trombolytics• Recombinant-tissue PA ( rt-PA) Alteplase
  • 35. Presented by Dr. Mohana Krishna